The era of CFTR modulators: improvements made and remaining challenges
Sara Cuevas Ocaña, Onofrio Laselva, Julie Avolio, Raffaella Nenna
Abstract
<b>The entry into the clinic of CFTR modulators such as TRIKAFTA has significantly improved life for ∼90% CF patients carrying one or two F508del mutations but challenges remain for rare <i>CFTR</i> mutations and the management of lung infections @SaraOcana1</b>https://bit.ly/3aRafQF
Topics & Concepts
Cystic fibrosisMedicineMutationBiologyInternal medicineGeneticsGeneCystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchTracheal and airway disorders